# BIONEXUS GENE LAB CORP (BGLC)

> Institutional ownership reported to the SEC as of Q2 2026, from Form 13F filings. Source: https://holderbook.com/stocks/BGLC/

- Reporting holders: 3
- Reported value: $27.2K
- Shares held by institutions: 14,385 of 2,933,442 outstanding
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [HRT FINANCIAL LP](https://holderbook.com/funds/1475597-hrt-financial-lp/) | $27.0K | 14,283 | 0.0% | 1 |
| [UBS Group AG](https://holderbook.com/funds/1610520-ubs-group-ag/) | $197 | 101 | 0.0% | 2 |
| [Caitong International Asset Management Co., Ltd](https://holderbook.com/funds/1963355-caitong-international-asset-management-co-ltd/) | $2 | 1 | 0.0% | 1 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q2 2026 | 3 | $27.2K |
| Q1 2026 | 2 | $499 |
| Q4 2025 | 1 | $188.9K |
| Q3 2025 | 2 | $121.9K |
| Q2 2025 | 1 | $29.4K |
| Q1 2025 | 4 | $37.3K |
| Q4 2024 | 6 | $49.8K |
| Q3 2024 | 4 | $58.2K |
| Q2 2024 | 3 | $30.3K |
| Q1 2024 | 4 | $70.7K |
| Q4 2023 | 5 | $55.9K |
| Q3 2023 | 5 | $171.4K |